ProMIS Neurosciences Inc.

ProMIS International Inc. is a biotechnology company focused on developing antibody therapies, therapeutic vaccines, and other antibody-derived treatments for neurodegenerative and misfolded protein diseases. These conditions include Alzheimer's disease (AD), multiple system atrophy (MSA), amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Parkinson's disease (PD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and schizophrenia. The company's approach addresses the common biological cause where normally functional proteins misfold, leading to neuronal degeneration and death. ProMIS utilizes a patented technology platform, the EpiSelect™ Platform Technology, which leverages computational power, in silico discovery, and artificial intelligence. This platform identifies specific conformational epitopes that are exposed only on the toxic, misfolded forms of a protein, not on its properly folded counterpart. These disease-specific epitopes (DSEs) are then used to create therapeutic antibody candidates. These candidates are designed to selectively target the toxic misfolded proteins, avoiding interference with the essential functions of healthy proteins. The in silico modeling of protein misfolding allows for the prediction of target epitopes, enhancing the speed and quality of therapeutic antibody development compared to earlier methods.